Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ipsen Group

Ipsen Group
1929 FOUNDED
PUBLIC STATUS
5K-10K EMPLOYEES
IPN STOCK SYMBOL
24 INVESTMENTS
$91.71 SHARE PRICE (As of Friday Closing)
Description

Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Website
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Other Commercial Services
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 65, quai Georges Gorse
  • 92100 Boulogne Billancourt
  • France

+33 01 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ipsen Group’s full profile, request a free trial.

Ipsen Group Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$81.95 - $143.62 $7.62B $90.82 $5.66 156K 83M

Ipsen Group Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 11,333,074 10,595,811 10,047,191 5,899,102
Revenue 2,870,212 2,771,268 2,268,724 1,848,480
EBITDA 739,625 757,957 546,402 378,081
Net Income 470,080 459,636 307,090 249,878
Total Assets 5,462,815 3,863,418 3,685,486 2,548,799
Total Debt 1,280,941 383,894 434,532 319,822
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ipsen Group Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Ipsen Group‘s full profile, request access.

Request full access to PitchBook

Ipsen Group Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pharming Group Formerly VC-backed Leiden, Netherlands 000 00000 000000000 00000
000000 Corporation Paris, France 000000 000000000000
000000000 Private Equity-Backed Milan, Italy 0000 000000000000
00000 000000000000 Private Equity-Backed Atlanta, GA 000 000.00 0&0
00000000 Corporate Backed or Acquired Basel, Switzerland 000000 000000000000
To view this company’s complete list of competitors, request access »

Ipsen Group Investments & Acquisitions (24)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 00000000 17-Jul-2019 00000 00000 00 0000 Drug Discovery 00000000 0000000 00.0
000000000 00000000 18-Apr-2019 000000000000000000 00.000 Biotechnology 00000 0000
000000 (0000 00000 08-May-2017 000000000 00000 00 000.00 Pharmaceuticals 00000 0000
000000000 00000000 03-Apr-2017 000000000 00000 00 00.000 Drug Discovery 00000 0000
Rhythm Pharmaceuticals 16-Feb-2017 Mezzanine 0000 Biotechnology
To view this company’s complete investment and acquisition history, request access »

Ipsen Group Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 16-Feb-2017 000000000 0000 Completed
  • 7 buyers
00000 000000000000 13-Aug-2015 00000 00000 00 0000 Completed
  • 8 buyers
000000 00000000000 13-Aug-2015 00000 00000 00 0000 Completed
  • 8 buyers
000000 00000000000 29-Jul-2013 00000 00000 00 0000 Completed
  • 7 buyers
Radius Health 16-Dec-2011 Later Stage VC 000.00 Completed
  • 10 buyers
To view this company’s complete exits history, request access »

Ipsen Group Subsidiaries (4)

Company Name Industry Location Founded
Clementia Pharmaceuticals Biotechnology Montreal, Canada 2010
00000000000 000000 Biotechnology Berlin, Germany 0000
000000 00000000000 Drug Discovery London, United Kingdom 0000
00000 000000000000 Biotechnology Basking Ridge, NJ 0000
To view this company’s complete subsidiary history, request access »

Ipsen Group Executive Team (24)

Name Title Board
Seat
Contact
Info
Aymeric Le Chatelier Interim Chief Executive Officer, Chief Financial Officer and Executive Vice President
Richard Paulson Executive Vice President & Chief Executive Officer, North America
Dominique Laymand Executive Vice-President & Chief Ethics and Compliance Officer
Alexandre LeBeaut MD Executive Vice President, Research & Development & Chief Scientific Officer
Priyanka Rohatgi Ph.D Executive

11 Former Executives

You’re viewing 5 of 24 executives. Get the full list »

Ipsen Group Board Members (6)

Name Representing Role Since Contact
Info
0000 00000000 Ipsen Group Board Member 000 0000
00000 00000000 Self Board Member 000 0000
0000 00 0000000 Self Chairman 000 0000
0000000 000000 Ipsen Group General Secretary & Board Member 000 0000

2 Former Board Members

You’re viewing 4 of 6 board members. Get the full list »